Cart
sales@molnova.com
AZD8931 diFuMaric acid
CAS No. 1196531-39-1
AZD8931 diFuMaric acid ( —— )
Catalog No. M22731 CAS No. 1196531-39-1
AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 672 | In Stock |
|
| 50MG | 945 | In Stock |
|
| 100MG | 1278 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD8931 diFuMaric acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
-
DescriptionAZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR;ErbB2;ErbB3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1196531-39-1
-
Formula Weight706.1
-
Molecular FormulaC31H33ClFN5O11
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhaomei Mu,Teresa Klinowska,Xiaoshen Dong,et al.AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.J Exp Clin Cancer Res. 2014 May 30;33(1):47.
molnova catalog
related products
-
WHI-P154
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
-
Lifirafenib
Lifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
-
HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
